TherapeuticsMD (NASDAQ:TXMD) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report sent to investors on Wednesday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Performance

TXMD stock opened at $1.83 on Wednesday. The business has a 50 day moving average price of $1.91 and a 200 day moving average price of $2.10. TherapeuticsMD has a fifty-two week low of $1.43 and a fifty-two week high of $4.35.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Friday, May 10th. The company reported ($0.07) earnings per share for the quarter. The business had revenue of $0.31 million for the quarter.

Hedge Funds Weigh In On TherapeuticsMD

An institutional investor recently bought a new position in TherapeuticsMD stock. ADAR1 Capital Management LLC bought a new stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned about 2.57% of TherapeuticsMD as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.